PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...

Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...

Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...

Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.

SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- ...

Evidence demonstrates that SUBLOCADE supports long-term recovery from opioid use disorder (OUD) and is effective and safe. Publications highlight the importance of overcoming access barriers to ...

From Philly and the Pa. suburbs to South Jersey and Delaware, what would you like WHYY News to cover? Let us know! Prevention Point Philadelphia’s drop-in center on Kensington Avenue used to be a ...

Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE ® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) These FDA ...